Dewpoint Therapeutics Appoints Joel Sendek as Chief Financial Officer
- Sendek adds 30 years experience in biotechnology leadership
News provided by
Share this article
Share this article
BOSTON, Feb. 11, 2021 /PRNewswire/ Dewpoint Therapeutics, the biomolecular condensates company, today announced it has appointed Joel Sendek as Chief Financial Officer and Treasurer. As we accelerate our growth plans, Joel s financial expertise and leadership in fundraising and corporate finance for both private and public biotech companies will be invaluable, said Ameet Nathwani, M.D., Chief Executive Officer of Dewpoint Therapeutics. I am delighted to welcome him to our rapidly growing team and look forward to the significant contributions he will make as we work to leverage biomolecular condensates to create medicines for some of the world s toughest diseases.